ICU Fellowship Vivas – MH, Failure to Wean and Pancreatitis Dr Swapnil Pawar
Inguinal Hernia Dr Swapnil Pawar
Acute Pericarditis Dr Swapnil Pawar
Stopping Nasogastric feeds in ICU – Time for a CHANGE Dr Swapnil Pawar
ANTHARTIC Trial Dr Swapnil Pawar
CRICS-TRIGGERSEP Network and the ANTHARTIC Study Group
Even though controversies persist, targeted temperature management at 32 to 36°C remains recommended in patients with out-of-hospital cardiac arrest. Since it has beneficial effects on morbidity and mortality. However, targeted temperature management is associated with an increased risk of secondary infections and constitutes an independent risk factor for early ventilator-associated pneumonia.
The key early study suggesting the benefit of single-day administration of cefuroxime in patients with coma was performed more than 20 years ago. Few studies have been conducted since, including one single-centre, small, unblinded, prospective, randomized, controlled trial8 and one prospective, nonrandomized cohort study. Moreover, several retrospective studies showed a decreased incidence of infectious complications and decreased related morbidity when antibiotic therapy was given early to patients receiving targeted temperature management after cardiac arrest.
A randomized trial has previously shown that short-term treatment with amoxicillin-clavulanate failed to prevent ventilator-associated pneumonia in patients with out of hospital cardiac arrest as compared with placebo (50% in both groups). This single-centre trial was underpowered and limited by the absence of adjudication of secondary infections.
Authors hypothesized that systematic administration of empirical 2-day antibiotic therapy could prevent early ventilator-associated pneumonia and related complications in patients with out-of-hospital cardiac arrest treated with targeted temperature management, without clinically or biologically significant adverse effects, and could reduce intensive care unit (ICU) and hospital lengths of stay and medical costs related to ventilator-associated pneumonia.
Adult patients (>18 years of age) hospitalized in the ICU after an out-of-hospital cardiac arrest with shockable rhythm and treated with 32–34°C from 16 French ICUs were eligible.
Design: Double-blind, placebo-controlled, randomized controlled trial. Computer-generated, web-based randomization, stratified according to center, with a fixed block size of four units. Randomization within 6 h of return of spontaneous circulation
Intervention: Amoxycillin-clavulanic acid, 1.2 g, IV, 8 hourly for 2 days
Control: Normal saline as placebo
Common to both groups: Rapid induction of hypothermia (cold saline infusion); the temperature was maintained at 32 to 34°C for 24 to 36 hours. Sedation protocol, the use of neuromuscular blockade agents, and the method of targeted temperature management left to clinician preferences. Patients who developed secondary infections were treated with appropriate antibiotics according to local guidelines.
Primary outcome: Early-onset ventilator-associated pneumonia defined as during the first 7 days of hospitalization. Clinical Pulmonary Infection Score and Sequential Organ Failure Assessment scores, chest radiography, arterial blood gas analysis, blood cultures, and quantitative sampling of the lower respiratory tract by BAL or tracheal aspirate culture before antibiotic administration. Three blinded senior intensivists with experience in VAP trials adjudicated on the presence of VAP. Clinical, radiological, and microbiological criteria.
Sample size based on an incidence of 68%, 25% reduction; for 90% power and type I error of 5%, 163 patients. Death as a competing event increased the sample size by 15% to 192
When the cut off for “early” VAP was 5 days: 17% vs. 31%; hazard ratio: 0.53; 95% CI, 0.30 to 0.95; P = 0.03.
Secondary outcomes (antibiotic vs. control):
Summary of main findings: Among patients resuscitated after of out-of-hospital cardiac arrests with a shockable rhythm who underwent targeted temperature management, two days of intravenous with amoxicillin-clavulanate significantly reduced the incidence of early ventilator-associated pneumonia (within 7 days) compared to placebo.
No difference in Late ventilator-associated pneumonia, other nosocomial infections, 28-d mortality, ICU LOS, ventilator-free days till day 28, intestinal acquisition of MDR organisms on the day. Percentage of antibiotic-free days tended to be lower in the group who had prophylactic antibiotics
Due to several limitations and underpowered sample size, this trial won’t change our practices.
Dr Swapnil Pawar November 17, 2019
Dr Jose Chacko & Dr Swapnil Pawar Stress-induced gastrointestinal ulcers are common among patients admitted to the intensive care unit (ICU). These ulcers impose significant morbidity and mortality, therefore, stress […]
Dr Swapnil Pawar July 14, 2021